Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Journal:

The Lancet Oncology

Published:

2026-01-13

DOI:

10.1016/s1470-2045(25)00643-6

Affiliations:

18

Authors:

19

Go to article

Institutions	Authors	Share
Jiangsu Hansoh Pharmaceutical Group Co., Ltd., China	3.000000	0.16
Jilin Province Cancer Hospital, China	2.000000	0.11
Xiangya Hospital, CSU, China	1.500000	0.08
Anhui Chest Hospital, China	1.000000	0.05
Shandong Cancer Hospital, China	1.000000	0.05
Shanghai Pulmonary Hospital, China	1.000000	0.05
Xinjiang Tumor Hospital, XJMU, China	1.000000	0.05
Henan Cancer Hospital, ZZU, China	1.000000	0.05
Nantong Tumor Hospital, China	1.000000	0.05
Wuhan Union Hospital, HUST, China	1.000000	0.05
The First Affiliated Hospital of Soochow University, China	1.000000	0.05
Cancer Hospital of Yunnan Province, China	1.000000	0.05
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.05
Linyi Cancer Hospital, China	1.000000	0.05
Harbin Medical University Cancer Hospital, China	1.000000	0.05
Hunan Cancer Hospital, China	0.500000	0.03

Interested in Oncology and Carcinogenesis?